{"hq_id":"hq-c-org-000517","name":"Polyethylene glycol 400 (PEG-400)","context":"human_adult","timestamp":"2026-05-01T19:43:58.170Z","risk_level":"low","risk_profile":{"magnitude":{"mean":0.2,"weightedMean":0.2,"std_dev":0,"confidence_interval_95":[0.2,0.2],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.2,"weight":0.35}]},"confidence":{"mean":0.5,"weightedMean":0.5,"std_dev":0,"confidence_interval_95":[0.5,0.5],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.5,"weight":0.35}]},"recency":{"mean":1,"weightedMean":1,"std_dev":0,"confidence_interval_95":[1,1],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":1,"weight":0.35}]},"methodology":{"mean":0.7,"weightedMean":0.7,"std_dev":0,"confidence_interval_95":[0.7,0.7],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.7,"weight":0.35}]},"specificity":{"mean":0.92,"weightedMean":0.92,"std_dev":0,"confidence_interval_95":[0.92,0.92],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.92,"weight":0.35}]},"consensus":{"exists":false,"strength":0,"disagreement_magnitude":0,"warning":"single_source_warning"}},"interpretation":{"summary":"Single source (HQ_DIRECT, 2026) indicates low risk.","confidence_note":"Evidence quality varies; interpretation requires caution.","context_note":null,"warning":"single_source_warning"},"sources":[],"warnings":["unmapped_classification:US FDA / EFSA (PEG-400 — polyethylene glycol 400 — FDA-approved pharmaceutical excipient (inactive ingredient database; used as oral, topical, and parenteral vehicle); EFSA 2016 ADI of 10 mg/kg bw/day for polyethylene glycols as food additives; no carcinogenicity classification by IARC, NTP, US EPA, or EFSA for PEG polymers; manufacturing process concern: ethylene oxide (IARC Group 1) and 1,4-dioxane (IARC Group 2B) are potential process impurities from ethoxylation — controlled by pharmacopeial specification limits (ICH Q3C); USP and EP specifications for residual ethylene oxide and 1,4-dioxane in PEG excipients):no carcinogenicity classification; fda-approved ph","unmapped_classification:EPA CTX / Genetox:genotoxicity: positive (ames: positive, 4 positive","unmapped_classification:EPA CTX / Genetox:genotoxicity: positive (ames: positive, 4 positive","single_source_warning"],"meta":{"synthesis_version":"1.0.0","config_version":"1.0.0","n_sources":1,"db_version":26,"warnings":["unmapped_classification:US FDA / EFSA (PEG-400 — polyethylene glycol 400 — FDA-approved pharmaceutical excipient (inactive ingredient database; used as oral, topical, and parenteral vehicle); EFSA 2016 ADI of 10 mg/kg bw/day for polyethylene glycols as food additives; no carcinogenicity classification by IARC, NTP, US EPA, or EFSA for PEG polymers; manufacturing process concern: ethylene oxide (IARC Group 1) and 1,4-dioxane (IARC Group 2B) are potential process impurities from ethoxylation — controlled by pharmacopeial specification limits (ICH Q3C); USP and EP specifications for residual ethylene oxide and 1,4-dioxane in PEG excipients):no carcinogenicity classification; fda-approved ph","unmapped_classification:EPA CTX / Genetox:genotoxicity: positive (ames: positive, 4 positive","unmapped_classification:EPA CTX / Genetox:genotoxicity: positive (ames: positive, 4 positive"]},"schema":"synthesis"}